Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics
Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics
复制标题
DOI：
10.1007/s12265-015-9655-z
复制
发表时间：
2015-11-01
影响因子：
3.4
通讯作者：
Homer-Vanniasinkam, Shervanthi
中科院分区：
文献类型：
--
作者：
De Siqueira, Jonathan;Zani, Izma Abdul;Homer-Vanniasinkam, Shervanthi
凝集素样氧化低密度脂蛋白受体-1（SR-E1，LOX-1，OLR 1）是近20年前首次发现的修饰脂蛋白颗粒的血管受体。从那时起，体外和体内研究已经证明LOX-1（可溶性形式（sLOX-1））与许多疾病（包括动脉粥样硬化、关节炎、高血压和先兆子痫）之间的关联。然而，将这些发现转化为常规临床使用的工具和药物取决于转化的临床前和临床研究，但此类研究仅在过去十年中才开始出现。在这篇综述中，我们确定了关键的临床应用和相应的标准，需要解决的有效使用LOX-1相关的探针和分子，为患者的利益，在不同的疾病状态。
Lectin-like oxidized low-density lipoprotein receptor-1 (SR-E1, LOX-1, OLR1) was first discovered as a vascular receptor for modified lipoprotein particles nearly 20 years ago. Since then, in vitro and in vivo studies have demonstrated an association between LOX-1, a soluble form (sLOX-1) and a number of diseases including atherosclerosis, arthritis, hypertension and pre-eclampsia. However, converting such discoveries into tools and drugs for routine clinical use is dependent on translational preclinical and clinical studies but such studies have only begun to emerge in the past decade. In this review, we identify the key clinical applications and corresponding criteria that need to be addressed for the effective use of LOX-1-related probes and molecules for patient benefit in different disease states.